SPRY

Ars Pharmaceuticals INC

-$288.9M

Net Activity

Institutions Holding

203

Popularity Rank

#2851

Avg Weight

0.09%

Total Value

$753.4M

Ownership Trend

203 institutions currently hold SPRY, with 97 net buyers and 81 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Neutral

Based on recent trading activity

Net Selling Institutions

81

Net Buying Institutions

97

Key Holders

Key Holders

Top 5 by Value

RC
Ra Capital Management, L.p.
$87.2M
OA
Orbimed Advisors LLC
$66.6M
RC
Rubric Capital Management LP
$64.2M
DM
Deerfield Management Company, L.p.
$60.3M
MM
Millennium Management LLC
$48.0M

Top 5 by Conviction

SO
SR One Capital Management, LP
3.52%
TC
Tyro Capital Management LLC
2.59%
OA
Orbimed Advisors LLC
1.36%
RC
Ra Capital Management, L.p.
0.92%
DM
Deerfield Management Company, L.p.
0.71%
View all 203 holding institutions

Quarterly Activity

Recent Activity

+$368.2M

Total Buy Value

$278.4M

Total Sell Value

New buy35
Trim58
Add62
Sold out23

97

Net Buyers

81

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

2

Filings (90d)

$284K

Total Est. Value

28K shares

Planned Shares

Last Filed 2026-06-12
FilerFiling DateEst. Value
Karas Eric2026-06-12$250K
Fitzpatrick Alexander A2026-06-12$34K

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。

Beneficial Ownership (13D/13G)

0

Active 5%+ Holders

Data as of 2026-07-14
Reporting PersonTypeFiling Date% of Class
Integrated Core Strategies (US) LLC13G/A2026-07-142.5%

View all Schedule 13D/13G filings

Material Events (8-K)

1

Filings (14d)

Data as of 2026-07-07
2026-07-07

ARS Pharmaceuticals has announced a leadership change. On July 7, 2026, the board appointed President Donn Casale as CEO, effective immediately, replacing Richard Lowenthal, who was terminated without cause. Casale also joined the board as a Class III director until the 2029 annual meeting.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding ARS PHARMACEUTICALS INC (SPRY)?
Major stakeholders currently include Ra Capital Management, L.p. ($87.2M), Orbimed Advisors LLC ($66.6M), Rubric Capital Management LP ($64.2M). Based on the latest 13F filings, there are a total of 203 tracked investment funds and institutions maintaining positions in SPRY.
What is the overall institutional sentiment toward SPRY recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $288.9M, driven by 97 managers accumulating shares while 81 reduced their exposure.
Which institutions have been selling or reducing their SPRY positions?
In the latest period, 58 funds trimmed their holdings, and 23 managers completely exited their positions. The aggregate reported sell value was $278.4M.
Are there any notable investors adding SPRY to their portfolios?
Yes, buying activity remains notable. 35 institutions opened new positions in {ticker}, and 62 existing holders added to their shares. The total reported buy value for the quarter amounted to $368.2M.

Related Stocks

Trending Institutional Adds

The most-added stocks by 13F institutions this quarter

MSFT

Microsoft CORP

Institutions Holding

6,150

Total reported value

$2.1T

3245 13F institutions increased their position this quarter

View detail
AMZN

Amazon.com INC

Institutions Holding

5,957

Total reported value

$1.5T

3028 13F institutions increased their position this quarter

View detail
NVDA

Nvidia CORP

Institutions Holding

5,764

Total reported value

$3.0T

2743 13F institutions increased their position this quarter

View detail